Here's What Key Metrics Tell Us About Bristol Myers (BMY) Q4 EarningsZacks Investment Research • 02/06/25
Bristol Myers Squibb (BMY) Beats Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/06/25
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost CutsBenzinga • 02/06/25
Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%.Investors Business Daily • 02/06/25
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024Business Wire • 02/06/25
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and BreyanziZacks Investment Research • 02/03/25
What Analyst Projections for Key Metrics Reveal About Bristol Myers (BMY) Q4 EarningsZacks Investment Research • 02/03/25
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular CarcinomaBusiness Wire • 01/31/25
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular LymphomaBusiness Wire • 01/31/25
Bristol Myers Squibb (BMY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 01/30/25
Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo MonotherapyBusiness Wire • 01/25/25
Bristol Myers Squibb (BMY) Stock Dips While Market Gains: Key FactsZacks Investment Research • 01/17/25
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drugCNBC • 01/15/25
Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/13/25
ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid TumorsGlobeNewsWire • 01/13/25